14 research outputs found
If Human Brain Organoids Are the Answer to Understanding Dementia, What Are the Questions?
Because our beliefs regarding our individuality, autonomy, and personhood are intimately bound up with our brains, there is a public fascination with cerebral organoids, the "mini-brain," the "brain in a dish". At the same time, the ethical issues around organoids are only now being explored. What are the prospects of using human cerebral organoids to better understand, treat, or prevent dementia? Will human organoids represent an improvement on the current, less-than-satisfactory, animal models? When considering these questions, two major issues arise. One is the general challenge associated with using any stem cell-generated preparation for in vitro modelling (challenges amplified when using organoids compared with simpler cell culture systems). The other relates to complexities associated with
defining and understanding what we mean by the term "dementia." We discuss 10 puzzles, issues, and stumbling blocks
to watch for in the quest to model "dementia in a dish."The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Australian Dementia Stem Cell Consortium has
received generous start-up travel grants from the Australian
NHMRC National Institute for Dementia Research. Authors have been supported by Dementia Australia Research
Foundation, Yulgilbar Alzheimer’s Research Program, DHB
Foundation (AP), Brain Foundation (DH, AP), the C.F. Leung
Memorial Trust (AP), the University of Melbourne (AP) and
Operational Infrastructure Support from the Victorian
Government (DH, AP), Monash University (AG), JO and JR
Wicking Trust (Equity Trustees) (ALC and AEK), University
of Sydney (MV), and generous gifts from the Sinclair, Smith
and Jolly families (MV). AEK is supported by a National Health
and Medical Research Council (NHMRC) of Australia Boosting
Dementia Research Leadership Fellowship (APP1136913). AG
is supported by a NHMRC-ARC Dementia Research
Development Fellowship (GNT1097461). AP is supported by
an ARC Future Fellowship (FT140100047) and a NHMRC
Senior Research Fellowship (1154389). LO is supported by a
NHMRC of Australia Boosting Dementia Research Leadership
Fellowship (APP1135720). MV is supported by a NHMRC
Career Development Fellowship (APP1112813). VG is supported by Australian Research Council’s Discovery Early
Career Researcher Award (DE180100775)
Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients
Expression and role of CoREST3 in neurodevelopment and neurodegeneration
Repressor element-1 silencing transcription factor (REST) is a transcriptional repressor involved in neurodevelopment and neuroprotection that forms a complex with the corepressor of REST1 (CoREST1), CoREST2 and CoREST3 (encoded by RCOR1, RCOR2 and RCOR3, respectively). Emerging evidence suggests the CoREST family have the ability to target unique genes, in a RESTindependent manner, in various neural and glial cell types at different stages of development. There is limited knowledge on expression and function of CoREST3 in neurodevelopment and neurodegeneration, particularly in humans. This study used 2D and 3D human pluripotent stem cell (hPSC) models to interrogate RCOR3 gene expression levels in human neurons using RT-qPCR. RCOR3 expression was shown to significantly increase in glutamatergic cortical and GABAergic ventral forebrain neurons, mature functional NGN2 induced neurons and a trend for an increase in 3D cerebral organoids. CoREST3 was shown to have an age-related and region-specific expression pattern in the aging rat brain, with expression in the prefrontal cortex increasing in adult rats (postnatal day 96) and in the caudate putamen in aged rats (~14 months) via western blotting. CoREST3 expression was analysed in an AD post-mortem tissue of four brain regions that are affected with varying severity via western blot analysis. The brain regions, in order of decreasing neuronal loss, were the superior temporal gyrus (STG), inferior temporal gyrus (ITG), precuneus (PRE) and primary visual cortex (PVC) (n = 23 AD, n = 18 matched controls). Neuronal counts showed a significant reduction only in the STG. The full-length CoREST3, isoform A, was significantly decreased by ~ 30 % in AD compared to age- and sex-matched controls. RCOR3 shRNA knockdown in cortical neurons derived from hPSCs resulted in a trend for an increase in the cortical neural progenitor marker, PAX6, and neuronal markers TUBB3 (encodes Ăź-III-tubulin) and MAP2, in addition to a trend for increased neurite length. A significant increase in HDAC2 expression was also observed in cortical neurons following CoREST3 gene knockdown. In summary, our findings are the first to show an increase of RCOR3 expression with human embryonic neural differentiation, CoREST3 to be expressed in healthy adult brain and expression disrupted in AD. In addition to a potential neuroprotective role for CoREST3 in the regulation HDAC2 expression, which may be diminished in AD. Better understanding the regulatory networks of the brain will deepen our understanding of the biological basis of neurodegeneration
More than a Corepressor: The Role of CoREST Proteins in Neurodevelopment
The molecular mechanisms governing normal neurodevelopment are tightly regulated by the action of transcription factors. Repressor element 1 (RE1) silencing transcription factor (REST) is widely documented as a regulator of neurogenesis that acts by recruiting corepressor proteins and repressing neuronal gene expression in non-neuronal cells. The REST corepressor 1 (CoREST1), CoREST2, and CoREST3 are best described for their role as part of the REST complex. However, recent evidence has shown the proteins have the ability to repress expression of distinct target genes in a REST-independent manner. These findings indicate that each CoREST paralogue may have distinct and critical roles in regulating neurodevelopment and are more than simply REST corepressors, whereby they act as independent repressors orchestrating biological processes during neurodevelopment
Innovations advancing our understanding of microglia in Alzheimer\u27s disease: From in vitro to in vivo models
Microglia have been implicated in Alzheimer\u27s disease (AD) pathogenesis through the identification of risk factor genes that are specifically or predominantly expressed in this cell type. Additional evidence suggests that microglia undergo dramatic morphological and phenotypic state changes during AD progression, as observed in human post-mortem tissue and animal model research. Although valuable, these studies are often hampered by either representing one time point in human tissue (end point) or because of the lack of conservation between species of microglial transcriptomes, proteomes and cell states. Thus, the development and application of novel human model systems have been beneficial in the study of microglia in neurodegeneration. Recent innovations include the use of human pluripotent stem cell (hPSC)-derived microglia in 2D or 3D culture systems, the transdifferentiation of microglia from patient monocytes and the xenotransplantation of hPSC-derived microglia into mouse brains. This review summarizes the recent innovations that have advanced our understanding of microglia in AD, through the use of single-cell RNA sequencing, hPSC-derived microglia culture within brain organoids and xenotransplantation into mouse brain. Through outlining the strengths and limitations of these approaches, we provide recommendations that will aid future endeavours in advancing our understanding of the complex role of microglia in AD onset and progression. (Figure presented.
Transgene and Chemical Transdifferentiation of Somatic Cells for Rapid and Efficient Neurological Disease Cell Models
For neurological diseases, molecular and cellular research relies on the use of model systems to investigate disease processes and test potential therapeutics. The last decade has witnessed an increase in the number of studies using induced pluripotent stem cells to generate disease relevant cell types from patients. The reprogramming process permits the generation of a large number of cells but is potentially disadvantaged by introducing variability in clonal lines and the removal of phenotypes of aging, which are critical to understand neurodegenerative diseases. An under-utilized approach to disease modeling involves the transdifferentiation of aged cells from patients, such as fibroblasts or blood cells, into various neural cell types. In this review we discuss techniques used for rapid and efficient direct conversion to neural cell types. We examine the limitations and future perspectives of this rapidly advancing field that could improve neurological disease modeling and drug discovery
An Optimized Direct Lysis Gene Expression Microplate Assay and Applications for Disease, Differentiation, and Pharmacological Cell-Based Studies
Routine cell culture reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) gene expression analysis is limited in scalability due to minimum sample requirement and multistep isolation procedures. In this study, we aimed to optimize and apply a cost-effective and rapid protocol for directly sampling gene expression data from microplate cell cultures. The optimized protocol involves direct lysis of microplate well population followed by a reduced thermocycler reaction time one-step RT-qPCR assay. In applications for inflammation and stress-induced cell-based models, the direct lysis RT-qPCR microplate assay was utilized to detect IFN1 and PPP1R15A expression by poly(I:C) treated primary fibroblast cultures, IL6 expression by poly(I:C) iPSC-derived astrocytes, and differential PPP1R15A expression by ER-stressed vanishing white-matter disease patient induced pluripotent stem cell (iPSC)-derived astrocytes. Neural differentiation recipe optimizations were performed with SYN1 and VGLUT1 expression in neuronal cultures, and S100B, GFAP, and EAAT1 expression in astrocyte differentiations. The protocol provides microplate gene expression results from cell lysate to readout within ~35 min, with comparable cost to routine RT-qPCR, and it may be utilized to support laboratory cell-based assays in basic and applied scientific and medical fields of research including stem-cell differentiation, cell physiology, and drug mechanism studies
Edaravone and mitochondrial transfer as potential therapeutics for vanishing white matter disease astrocyte dysfunction
Introduction: Previous research has suggested that vanishing white matter disease (VWMD) astrocytes fail to fully differentiate and respond differently to cellular stresses compared to healthy astrocytes. However, few studies have investigated potential VWMD therapeutics in monoculture patient-derived cell-based models. Methods: To investigate the impact of alterations in astrocyte expression and function in VWMD, astrocytes were differentiated from patient and control induced pluripotent stem cells and analyzed by proteomics, pathway analysis, and functional assays, in the absence and presence of stressors or potential therapeutics. Results: Vanishing white matter disease astrocytes demonstrated significantly reduced expression of astrocyte markers and markers of inflammatory activation or cellular stress relative to control astrocytes. These alterations were identified both in the presence and absence of polyinosinic:polycytidylic acid stimuli, which is used to simulate viral infections. Pathway analysis highlighted differential signaling in multiple pathways in VWMD astrocytes, including eukaryotic initiation factor 2 (EIF2) signaling, oxidative stress, oxidative phosphorylation (OXPHOS), mitochondrial function, the unfolded protein response (UPR), phagosome regulation, autophagy, ER stress, tricarboxylic acid cycle (TCA) cycle, glycolysis, tRNA signaling, and senescence pathways. Since oxidative stress and mitochondrial function were two of the key pathways affected, we investigated whether two independent therapeutic strategies could ameliorate astrocyte dysfunction: edaravone treatment and mitochondrial transfer. Edaravone treatment reduced differential VWMD protein expression of the UPR, phagosome regulation, ubiquitination, autophagy, ER stress, senescence, and TCA cycle pathways. Meanwhile, mitochondrial transfer decreased VWMD differential expression of the UPR, glycolysis, calcium transport, phagosome formation, and ER stress pathways, while further modulating EIF2 signaling, tRNA signaling, TCA cycle, and OXPHOS pathways. Mitochondrial transfer also increased the gene and protein expression of the astrocyte marker, glial fibrillary acidic protein (GFAP) in VWMD astrocytes. Conclusion: This study provides further insight into the etiology of VWMD astrocytic failure and suggests edaravone and mitochondrial transfer as potential candidate VWMD therapeutics that can ameliorate disease pathways in astrocytes related to oxidative stress, mitochondrial dysfunction, and proteostasis
If Human Brain Organoids Are the Answer to Understanding Dementia, What Are the Questions?
© The Author(s) 2020. Because our beliefs regarding our individuality, autonomy, and personhood are intimately bound up with our brains, there is a public fascination with cerebral organoids, the “mini-brain,” the “brain in a dish”. At the same time, the ethical issues around organoids are only now being explored. What are the prospects of using human cerebral organoids to better understand, treat, or prevent dementia? Will human organoids represent an improvement on the current, less-than-satisfactory, animal models? When considering these questions, two major issues arise. One is the general challenge associated with using any stem cell–generated preparation for in vitro modelling (challenges amplified when using organoids compared with simpler cell culture systems). The other relates to complexities associated with defining and understanding what we mean by the term “dementia.” We discuss 10 puzzles, issues, and stumbling blocks to watch for in the quest to model “dementia in a dish.